Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Aine McKillop; NA Duffy; JR Lindsay; BD Green; Steven Patterson; Finbarr O'Harte; PM Bell; Peter Flatt

doi:10.1530/EJE-09-0547

Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Aine McKillop, NA Duffy, JR Lindsay, BD Green, Steven Patterson, Finbarr O'Harte, PM Bell, Peter Flatt

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P

Original language	English
Pages (from-to)	877-885
Journal	European Journal of Endocrinology
Volume	16
Issue number	6
DOIs	https://doi.org/10.1530/EJE-09-0547
Publication status	Published (in print/issue) - 15 Sept 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-09-0547

Cite this

McKillop, A., Duffy, NA., Lindsay, JR., Green, BD., Patterson, S., O'Harte, F., Bell, PM., & Flatt, P. (2009). Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. European Journal of Endocrinology, 16(6), 877-885. https://doi.org/10.1530/EJE-09-0547

@article{934f8404294a4488a5366e62f26c9899,

title = "Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.",

abstract = "BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P",

author = "Aine McKillop and NA Duffy and JR Lindsay and BD Green and Steven Patterson and Finbarr O'Harte and PM Bell and Peter Flatt",

year = "2009",

month = sep,

day = "15",

doi = "10.1530/EJE-09-0547",

language = "English",

volume = "16",

pages = "877--885",

journal = "European Journal of Endocrinology",

issn = "1479-683X",

publisher = "BioScientifica",

number = "6",

}

McKillop, A, Duffy, NA, Lindsay, JR, Green, BD, Patterson, S, O'Harte, F, Bell, PM & Flatt, P 2009, 'Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.', European Journal of Endocrinology, vol. 16, no. 6, pp. 877-885. https://doi.org/10.1530/EJE-09-0547

Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. / McKillop, Aine; Duffy, NA; Lindsay, JR et al.
In: European Journal of Endocrinology, Vol. 16, No. 6, 15.09.2009, p. 877-885.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

AU - McKillop, Aine

AU - Duffy, NA

AU - Lindsay, JR

AU - Green, BD

AU - Patterson, Steven

AU - O'Harte, Finbarr

AU - Bell, PM

AU - Flatt, Peter

PY - 2009/9/15

Y1 - 2009/9/15

N2 - BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P

AB - BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P

U2 - 10.1530/EJE-09-0547

DO - 10.1530/EJE-09-0547

M3 - Article

SN - 1479-683X

VL - 16

SP - 877

EP - 885

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 6

ER -

Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this